WO1995003313A1 - Nouveaux derives de benzylamines silylees, leurs sels, leurs procedes de fabrication et les compositions pharmaceutiques les renfermant - Google Patents
Nouveaux derives de benzylamines silylees, leurs sels, leurs procedes de fabrication et les compositions pharmaceutiques les renfermant Download PDFInfo
- Publication number
- WO1995003313A1 WO1995003313A1 PCT/FR1994/000921 FR9400921W WO9503313A1 WO 1995003313 A1 WO1995003313 A1 WO 1995003313A1 FR 9400921 W FR9400921 W FR 9400921W WO 9503313 A1 WO9503313 A1 WO 9503313A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- dimethyl
- ethyl
- derivative
- carbon atoms
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 118
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 13
- 150000003839 salts Chemical class 0.000 title claims abstract description 13
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 6
- 150000003939 benzylamines Chemical class 0.000 title abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 94
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract description 5
- 150000004677 hydrates Chemical class 0.000 claims abstract description 3
- 239000012453 solvate Substances 0.000 claims abstract description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 165
- -1 hydrocarbon radical Chemical class 0.000 claims description 90
- 238000002360 preparation method Methods 0.000 claims description 51
- 150000001412 amines Chemical class 0.000 claims description 39
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 33
- 125000004432 carbon atom Chemical group C* 0.000 claims description 31
- 239000004215 Carbon black (E152) Substances 0.000 claims description 23
- 229930195733 hydrocarbon Natural products 0.000 claims description 23
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 22
- 125000003118 aryl group Chemical group 0.000 claims description 18
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 18
- 229910052794 bromium Inorganic materials 0.000 claims description 17
- 229910052801 chlorine Inorganic materials 0.000 claims description 17
- 239000000460 chlorine Chemical group 0.000 claims description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 15
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 13
- 150000002825 nitriles Chemical class 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 12
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 230000002265 prevention Effects 0.000 claims description 11
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 9
- 201000001320 Atherosclerosis Diseases 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- 229910052740 iodine Inorganic materials 0.000 claims description 9
- 239000011630 iodine Substances 0.000 claims description 9
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- 238000007254 oxidation reaction Methods 0.000 claims description 8
- 239000001301 oxygen Substances 0.000 claims description 8
- 239000003638 chemical reducing agent Substances 0.000 claims description 7
- 229910052731 fluorine Inorganic materials 0.000 claims description 7
- 230000003647 oxidation Effects 0.000 claims description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 239000011737 fluorine Chemical group 0.000 claims description 5
- 238000006268 reductive amination reaction Methods 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 150000003573 thiols Chemical class 0.000 claims description 5
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 4
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 4
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 230000007170 pathology Effects 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 150000003254 radicals Chemical class 0.000 claims description 4
- 125000004434 sulfur atom Chemical group 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 150000003852 triazoles Chemical class 0.000 claims description 4
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical group ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 3
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims description 3
- 125000004423 acyloxy group Chemical group 0.000 claims description 3
- 230000002538 fungal effect Effects 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 230000000977 initiatory effect Effects 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 238000005502 peroxidation Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- VOLGAXAGEUPBDM-UHFFFAOYSA-N $l^{1}-oxidanylethane Chemical compound CC[O] VOLGAXAGEUPBDM-UHFFFAOYSA-N 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 241000222122 Candida albicans Species 0.000 claims description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 2
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical compound F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 102000000853 LDL receptors Human genes 0.000 claims description 2
- 108010001831 LDL receptors Proteins 0.000 claims description 2
- 208000031888 Mycoses Diseases 0.000 claims description 2
- 229910017912 NH2OH Inorganic materials 0.000 claims description 2
- 230000005856 abnormality Effects 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 125000004414 alkyl thio group Chemical group 0.000 claims description 2
- 238000005576 amination reaction Methods 0.000 claims description 2
- 150000005840 aryl radicals Chemical class 0.000 claims description 2
- 229940095731 candida albicans Drugs 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 230000007812 deficiency Effects 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 208000030159 metabolic disease Diseases 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 150000002923 oximes Chemical class 0.000 claims description 2
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 2
- 230000010410 reperfusion Effects 0.000 claims description 2
- 150000003457 sulfones Chemical class 0.000 claims description 2
- 150000003568 thioethers Chemical class 0.000 claims description 2
- 230000000472 traumatic effect Effects 0.000 claims description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 9
- 241001225321 Aspergillus fumigatus Species 0.000 claims 1
- 101100516568 Caenorhabditis elegans nhr-7 gene Proteins 0.000 claims 1
- 241000893980 Microsporum canis Species 0.000 claims 1
- 241001609979 Trichophyton quinckeanum Species 0.000 claims 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims 1
- 229940091771 aspergillus fumigatus Drugs 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 144
- 239000003921 oil Substances 0.000 description 131
- 235000019198 oils Nutrition 0.000 description 131
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 105
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 93
- 239000000243 solution Substances 0.000 description 78
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 72
- 239000000047 product Substances 0.000 description 70
- 238000000746 purification Methods 0.000 description 70
- 239000000377 silicon dioxide Substances 0.000 description 69
- 239000000543 intermediate Substances 0.000 description 67
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 64
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 60
- 230000015572 biosynthetic process Effects 0.000 description 53
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 50
- 238000004458 analytical method Methods 0.000 description 49
- 238000003786 synthesis reaction Methods 0.000 description 43
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
- HUAJEFRILCHZNU-SOFGYWHQSA-N 3-[[[(e)-6,6-dimethylhept-2-en-4-ynyl]-ethylamino]methyl]phenol Chemical compound CC(C)(C)C#C/C=C/CN(CC)CC1=CC=CC(O)=C1 HUAJEFRILCHZNU-SOFGYWHQSA-N 0.000 description 41
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 37
- 239000012074 organic phase Substances 0.000 description 35
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 34
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 32
- 235000019341 magnesium sulphate Nutrition 0.000 description 32
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 30
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 28
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 27
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 26
- 238000006243 chemical reaction Methods 0.000 description 25
- 238000009833 condensation Methods 0.000 description 25
- 230000005494 condensation Effects 0.000 description 25
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 24
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 21
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical class NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 21
- 239000000203 mixture Substances 0.000 description 21
- 239000003208 petroleum Substances 0.000 description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 239000012429 reaction media Substances 0.000 description 18
- 229910000027 potassium carbonate Inorganic materials 0.000 description 17
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 16
- 230000009467 reduction Effects 0.000 description 15
- 238000006722 reduction reaction Methods 0.000 description 15
- 239000002253 acid Substances 0.000 description 14
- 230000007935 neutral effect Effects 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 150000001299 aldehydes Chemical class 0.000 description 12
- 235000011181 potassium carbonates Nutrition 0.000 description 12
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 12
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 10
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 10
- 239000012280 lithium aluminium hydride Substances 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 125000006239 protecting group Chemical group 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 9
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 9
- 230000007062 hydrolysis Effects 0.000 description 9
- 238000006460 hydrolysis reaction Methods 0.000 description 9
- 238000011017 operating method Methods 0.000 description 9
- 230000009466 transformation Effects 0.000 description 9
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 8
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 8
- 239000008346 aqueous phase Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 8
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 102000007330 LDL Lipoproteins Human genes 0.000 description 7
- 150000001298 alcohols Chemical class 0.000 description 7
- 235000012000 cholesterol Nutrition 0.000 description 7
- 150000002148 esters Chemical group 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000012279 sodium borohydride Substances 0.000 description 7
- 229910000033 sodium borohydride Inorganic materials 0.000 description 7
- 229910000104 sodium hydride Inorganic materials 0.000 description 7
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- 0 CC*(CC=CC#CC(C)(C)C)Cc1cccc(N(C)CS(C)(C)c2ccccc2)c1 Chemical compound CC*(CC=CC#CC(C)(C)C)Cc1cccc(N(C)CS(C)(C)c2ccccc2)c1 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- 229910010084 LiAlH4 Inorganic materials 0.000 description 6
- 102000005782 Squalene Monooxygenase Human genes 0.000 description 6
- 108020003891 Squalene monooxygenase Proteins 0.000 description 6
- 150000001408 amides Chemical class 0.000 description 6
- 229910021529 ammonia Inorganic materials 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 238000010511 deprotection reaction Methods 0.000 description 6
- 229910052763 palladium Inorganic materials 0.000 description 6
- 239000012047 saturated solution Substances 0.000 description 6
- 229910000077 silane Inorganic materials 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000012039 electrophile Substances 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 235000015320 potassium carbonate Nutrition 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 4
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 4
- 150000000475 acetylene derivatives Chemical group 0.000 description 4
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 4
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 4
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 4
- RJCTVFQQNCNBHG-UHFFFAOYSA-N chloromethyl-dimethyl-phenylsilane Chemical compound ClC[Si](C)(C)C1=CC=CC=C1 RJCTVFQQNCNBHG-UHFFFAOYSA-N 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000007907 direct compression Methods 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 238000000921 elemental analysis Methods 0.000 description 4
- 239000002798 polar solvent Substances 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 229940031439 squalene Drugs 0.000 description 4
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 4
- 239000003039 volatile agent Substances 0.000 description 4
- 101150041968 CDC13 gene Proteins 0.000 description 3
- GQHTUMJGOHRCHB-UHFFFAOYSA-N DBU Substances C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 150000001350 alkyl halides Chemical class 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-DICFDUPASA-N dichloromethane-d2 Chemical compound [2H]C([2H])(Cl)Cl YMWUJEATGCHHMB-DICFDUPASA-N 0.000 description 3
- 125000002534 ethynyl group Chemical class [H]C#C* 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003859 lipid peroxidation Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 3
- 239000011736 potassium bicarbonate Substances 0.000 description 3
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 3
- 235000015497 potassium bicarbonate Nutrition 0.000 description 3
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 238000007127 saponification reaction Methods 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 230000001131 transforming effect Effects 0.000 description 3
- FHPKWQGOQVYTBY-UHFFFAOYSA-N (4-bromophenyl)-(chloromethyl)-dimethylsilane Chemical compound ClC[Si](C)(C)C1=CC=C(Br)C=C1 FHPKWQGOQVYTBY-UHFFFAOYSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- WJBRUWBYARXTCP-UHFFFAOYSA-N 3-chloropropyl-ethenyl-dimethylsilane Chemical compound C=C[Si](C)(C)CCCCl WJBRUWBYARXTCP-UHFFFAOYSA-N 0.000 description 2
- IAVREABSGIHHMO-UHFFFAOYSA-N 3-hydroxybenzaldehyde Chemical compound OC1=CC=CC(C=O)=C1 IAVREABSGIHHMO-UHFFFAOYSA-N 0.000 description 2
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 200000000007 Arterial disease Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229940123320 Cyclase inhibitor Drugs 0.000 description 2
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- HYVABZIGRDEKCD-UHFFFAOYSA-N N(6)-dimethylallyladenine Chemical compound CC(C)=CCNC1=NC=NC2=C1N=CN2 HYVABZIGRDEKCD-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 2
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 229910020667 PBr3 Inorganic materials 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 238000006069 Suzuki reaction reaction Methods 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 239000000010 aprotic solvent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- TVRFAOJPBXYIRM-UHFFFAOYSA-N bis(chloromethyl)-dimethylsilane Chemical compound ClC[Si](C)(C)CCl TVRFAOJPBXYIRM-UHFFFAOYSA-N 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical class B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- AHWPBMXFDSNCJV-UHFFFAOYSA-N chloromethyl-(4-methoxyphenyl)-dimethylsilane Chemical compound COC1=CC=C([Si](C)(C)CCl)C=C1 AHWPBMXFDSNCJV-UHFFFAOYSA-N 0.000 description 2
- AFAJDLRABYGOPM-UHFFFAOYSA-N chloromethyl-dimethyl-(2-methylphenyl)silane Chemical compound CC1=CC=CC=C1[Si](C)(C)CCl AFAJDLRABYGOPM-UHFFFAOYSA-N 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 2
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 2
- BZCOSCNPHJNQBP-OWOJBTEDSA-N dihydroxyfumaric acid Chemical compound OC(=O)C(\O)=C(/O)C(O)=O BZCOSCNPHJNQBP-OWOJBTEDSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- PSFDQSOCUJVVGF-UHFFFAOYSA-N harman Chemical compound C12=CC=CC=C2NC2=C1C=CN=C2C PSFDQSOCUJVVGF-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- XZFNWXWUNXBELP-UHFFFAOYSA-N n-(3-cyanophenyl)-2,2,2-trifluoroacetamide Chemical compound FC(F)(F)C(=O)NC1=CC=CC(C#N)=C1 XZFNWXWUNXBELP-UHFFFAOYSA-N 0.000 description 2
- HIZXLNAJYLZOEJ-UHFFFAOYSA-N n-(3-cyanophenyl)formamide Chemical compound O=CNC1=CC=CC(C#N)=C1 HIZXLNAJYLZOEJ-UHFFFAOYSA-N 0.000 description 2
- OZGNYLLQHRPOBR-DHZHZOJOSA-N naftifine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)C\C=C\C1=CC=CC=C1 OZGNYLLQHRPOBR-DHZHZOJOSA-N 0.000 description 2
- 229960004313 naftifine Drugs 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- IPNPIHIZVLFAFP-UHFFFAOYSA-N phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 2
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- FYRHIOVKTDQVFC-UHFFFAOYSA-M potassium phthalimide Chemical compound [K+].C1=CC=C2C(=O)[N-]C(=O)C2=C1 FYRHIOVKTDQVFC-UHFFFAOYSA-M 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 150000004756 silanes Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 2
- 229960002722 terbinafine Drugs 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- KJTLQQUUPVSXIM-ASLFEOCISA-N (3R)-3,5-dihydroxy-3-methyl(114C)pentanoic acid Chemical compound [14C](C[C@@](O)(C)CCO)(=O)O KJTLQQUUPVSXIM-ASLFEOCISA-N 0.000 description 1
- OTKLBYDBOQUSDZ-ZRDIBKRKSA-N (E)-N-[[3-(1-dimethylsilylprop-2-enoxy)phenyl]methyl]-N-ethyl-6,6-dimethylhept-2-en-4-yn-1-amine Chemical compound C(C)N(C\C=C\C#CC(C)(C)C)CC1=CC(=CC=C1)OC([SiH](C)C)C=C OTKLBYDBOQUSDZ-ZRDIBKRKSA-N 0.000 description 1
- DLONHCLOPCSIKK-UKTHLTGXSA-N (E)-N-[[3-(2-cyclohexylsilylpropan-2-yloxy)phenyl]methyl]-N-ethyl-6,6-dimethylhept-2-en-4-yn-1-amine Chemical compound C(C)N(C\C=C\C#CC(C)(C)C)CC1=CC(=CC=C1)OC([SiH2]C1CCCCC1)(C)C DLONHCLOPCSIKK-UKTHLTGXSA-N 0.000 description 1
- UYXYMZOIAASWMF-ZRDIBKRKSA-N (E)-N-[[3-[2-(2,6-dimethylphenyl)silylpropan-2-yloxy]phenyl]methyl]-N-ethyl-6,6-dimethylhept-2-en-4-yn-1-amine Chemical compound C(C)N(C\C=C\C#CC(C)(C)C)CC1=CC(=CC=C1)OC([SiH2]C1=C(C=CC=C1C)C)(C)C UYXYMZOIAASWMF-ZRDIBKRKSA-N 0.000 description 1
- HOVPGVFAUJTEGJ-ZRDIBKRKSA-N (E)-N-[[3-[2-(3,4-dimethylphenyl)silylpropan-2-yloxy]phenyl]methyl]-N-ethyl-6,6-dimethylhept-2-en-4-yn-1-amine Chemical compound C(C)N(C\C=C\C#CC(C)(C)C)CC1=CC(=CC=C1)OC([SiH2]C1=CC(=C(C=C1)C)C)(C)C HOVPGVFAUJTEGJ-ZRDIBKRKSA-N 0.000 description 1
- KPUVVPYLAOLYTE-CSKARUKUSA-N (E)-N-[[3-[2-(4-chlorophenyl)silylpropan-2-yloxy]phenyl]methyl]-N-ethyl-6,6-dimethylhept-2-en-4-yn-1-amine Chemical compound C(C)N(C\C=C\C#CC(C)(C)C)CC1=CC(=CC=C1)OC([SiH2]C1=CC=C(C=C1)Cl)(C)C KPUVVPYLAOLYTE-CSKARUKUSA-N 0.000 description 1
- DRSNDUPEOBFDPT-UKTHLTGXSA-N (E)-N-[[3-[dimethylsilyl-(2-methylphenyl)methoxy]phenyl]methyl]-N-ethyl-6,6-dimethylhept-2-en-4-yn-1-amine Chemical compound C(C)N(C\C=C\C#CC(C)(C)C)CC1=CC(=CC=C1)OC([SiH](C)C)C1=C(C=CC=C1)C DRSNDUPEOBFDPT-UKTHLTGXSA-N 0.000 description 1
- UMLRTYBCTPOEPO-PKNBQFBNSA-N (E)-N-[[3-[dimethylsilyl-(4-methoxyphenyl)methoxy]phenyl]methyl]-N-ethyl-6,6-dimethylhept-2-en-4-yn-1-amine Chemical compound C(C)N(C\C=C\C#CC(C)(C)C)CC1=CC(=CC=C1)OC([SiH](C)C)C1=CC=C(C=C1)OC UMLRTYBCTPOEPO-PKNBQFBNSA-N 0.000 description 1
- LPQXINJCGRDEBJ-CSKARUKUSA-N (E)-N-ethyl-6,6-dimethyl-N-[[3-(2-thiophen-3-ylsilylpropan-2-yloxy)phenyl]methyl]hept-2-en-4-yn-1-amine Chemical compound C(C)N(C\C=C\C#CC(C)(C)C)CC1=CC(=CC=C1)OC([SiH2]C1=CSC=C1)(C)C LPQXINJCGRDEBJ-CSKARUKUSA-N 0.000 description 1
- QTAIWXUHXUNPDD-PKNBQFBNSA-N (E)-N-ethyl-6,6-dimethyl-N-[[3-(trimethylsilylmethoxy)phenyl]methyl]hept-2-en-4-yn-1-amine Chemical compound C(C)N(C\C=C\C#CC(C)(C)C)CC1=CC(=CC=C1)OC[Si](C)(C)C QTAIWXUHXUNPDD-PKNBQFBNSA-N 0.000 description 1
- HIEWMTFLTLBTGM-PKNBQFBNSA-N (E)-N-ethyl-6,6-dimethyl-N-[[3-[2-(3-methylphenyl)silylpropan-2-yloxy]phenyl]methyl]hept-2-en-4-yn-1-amine Chemical compound C(C)N(C\C=C\C#CC(C)(C)C)CC1=CC(=CC=C1)OC([SiH2]C1=CC(=CC=C1)C)(C)C HIEWMTFLTLBTGM-PKNBQFBNSA-N 0.000 description 1
- LXCOUSZXBMUCOO-CSKARUKUSA-N (E)-N-ethyl-6,6-dimethyl-N-[[3-[2-(4-thiophen-3-ylphenyl)silylpropan-2-yloxy]phenyl]methyl]hept-2-en-4-yn-1-amine Chemical compound C(C)N(C\C=C\C#CC(C)(C)C)CC1=CC(=CC=C1)OC([SiH2]C1=CC=C(C=C1)C1=CSC=C1)(C)C LXCOUSZXBMUCOO-CSKARUKUSA-N 0.000 description 1
- ZNYKOHBJEVKMKQ-XYOKQWHBSA-N (E)-N-ethyl-6,6-dimethyl-N-[[3-[2-[2-(trifluoromethyl)phenyl]silylpropan-2-yloxy]phenyl]methyl]hept-2-en-4-yn-1-amine Chemical compound C(C)N(C\C=C\C#CC(C)(C)C)CC1=CC(=CC=C1)OC([SiH2]C1=C(C=CC=C1)C(F)(F)F)(C)C ZNYKOHBJEVKMKQ-XYOKQWHBSA-N 0.000 description 1
- ZCIZEPVNJOJCLZ-CSKARUKUSA-N (E)-N-ethyl-6,6-dimethyl-N-[[3-[2-[4-(trifluoromethyl)phenyl]silylpropan-2-yloxy]phenyl]methyl]hept-2-en-4-yn-1-amine Chemical compound C(C)N(C\C=C\C#CC(C)(C)C)CC1=CC(=CC=C1)OC([SiH2]C1=CC=C(C=C1)C(F)(F)F)(C)C ZCIZEPVNJOJCLZ-CSKARUKUSA-N 0.000 description 1
- IZHSKFHGFJCXEB-UKTHLTGXSA-N (E)-N-ethyl-N-[[3-[2-(2-methoxyphenyl)silylpropan-2-yloxy]phenyl]methyl]-6,6-dimethylhept-2-en-4-yn-1-amine Chemical compound C(C)N(C\C=C\C#CC(C)(C)C)CC1=CC(=CC=C1)OC([SiH2]C1=C(C=CC=C1)OC)(C)C IZHSKFHGFJCXEB-UKTHLTGXSA-N 0.000 description 1
- VOHOTMIMZXXJLK-ZRDIBKRKSA-N (E)-N-ethyl-N-[[3-[2-(4-ethynylphenyl)silylpropan-2-yloxy]phenyl]methyl]-6,6-dimethylhept-2-en-4-yn-1-amine Chemical compound C(C)N(C\C=C\C#CC(C)(C)C)CC1=CC(=CC=C1)OC([SiH2]C1=CC=C(C=C1)C#C)(C)C VOHOTMIMZXXJLK-ZRDIBKRKSA-N 0.000 description 1
- UKTMVXCKLCMAPQ-PKNBQFBNSA-N (E)-N-ethyl-N-[[3-[2-(4-fluoro-3-methylphenyl)silylpropan-2-yloxy]phenyl]methyl]-6,6-dimethylhept-2-en-4-yn-1-amine Chemical compound C(C)N(C\C=C\C#CC(C)(C)C)CC1=CC(=CC=C1)OC([SiH2]C1=CC(=C(C=C1)F)C)(C)C UKTMVXCKLCMAPQ-PKNBQFBNSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- VMKHBNKOHLSMNG-SOFGYWHQSA-N (e)-n-ethyl-6,6-dimethyl-n-[(3-nitrophenyl)methyl]hept-2-en-4-yn-1-amine Chemical compound CC(C)(C)C#C/C=C/CN(CC)CC1=CC=CC([N+]([O-])=O)=C1 VMKHBNKOHLSMNG-SOFGYWHQSA-N 0.000 description 1
- KIRGLCXNEVICOG-SOFGYWHQSA-N (e)-n-ethyl-6,6-dimethyl-n-[[3-[(4-thiophen-3-ylthiophen-2-yl)methoxy]phenyl]methyl]hept-2-en-4-yn-1-amine Chemical compound CC(C)(C)C#C/C=C/CN(CC)CC1=CC=CC(OCC=2SC=C(C=2)C2=CSC=C2)=C1 KIRGLCXNEVICOG-SOFGYWHQSA-N 0.000 description 1
- LNWXALCHPJANMJ-UHFFFAOYSA-N 1-(bromomethyl)-3-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC(CBr)=C1 LNWXALCHPJANMJ-UHFFFAOYSA-N 0.000 description 1
- CJMRIHBPWNKMLW-PKNBQFBNSA-N 1-[4-[2-[3-[[[(E)-6,6-dimethylhept-2-en-4-ynyl]-ethylamino]methyl]phenoxy]propan-2-ylsilyl]phenyl]ethanone Chemical compound C(C)N(C\C=C\C#CC(C)(C)C)CC1=CC(=CC=C1)OC([SiH2]C1=CC=C(C=C1)C(C)=O)(C)C CJMRIHBPWNKMLW-PKNBQFBNSA-N 0.000 description 1
- GMYBSGIHQYOVKW-UHFFFAOYSA-N 1-bromo-3-methoxy-3-methylbut-1-yne Chemical compound COC(C)(C)C#CBr GMYBSGIHQYOVKW-UHFFFAOYSA-N 0.000 description 1
- NRKYWOKHZRQRJR-UHFFFAOYSA-N 2,2,2-trifluoroacetamide Chemical compound NC(=O)C(F)(F)F NRKYWOKHZRQRJR-UHFFFAOYSA-N 0.000 description 1
- JYWKEVKEKOTYEX-UHFFFAOYSA-N 2,6-dibromo-4-chloroiminocyclohexa-2,5-dien-1-one Chemical compound ClN=C1C=C(Br)C(=O)C(Br)=C1 JYWKEVKEKOTYEX-UHFFFAOYSA-N 0.000 description 1
- VDYCSLZUDDHAIL-UHFFFAOYSA-N 2-[chloro(dimethyl)silyl]benzonitrile Chemical compound C[Si](C)(Cl)C1=CC=CC=C1C#N VDYCSLZUDDHAIL-UHFFFAOYSA-N 0.000 description 1
- HZTZJJXZOYDLIH-UHFFFAOYSA-N 2-[chloromethyl(dimethyl)silyl]benzonitrile Chemical compound ClC[Si](C)(C)C1=CC=CC=C1C#N HZTZJJXZOYDLIH-UHFFFAOYSA-N 0.000 description 1
- MEVXSUZBFYZPHZ-UHFFFAOYSA-N 2-amino-3-methyl-4h-imidazol-5-one;sulfuric acid Chemical compound OS(O)(=O)=O.CN1CC(=O)N=C1N MEVXSUZBFYZPHZ-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- PJAIMBYNTXNOCN-UHFFFAOYSA-N 3,6-dibromo-1h-indole Chemical compound BrC1=CC=C2C(Br)=CNC2=C1 PJAIMBYNTXNOCN-UHFFFAOYSA-N 0.000 description 1
- CVKOOKPNCVYHNY-UHFFFAOYSA-N 3-(bromomethyl)benzonitrile Chemical compound BrCC1=CC=CC(C#N)=C1 CVKOOKPNCVYHNY-UHFFFAOYSA-N 0.000 description 1
- FYYXCZJXTALUJA-UKTHLTGXSA-N 3-[[[(E)-6,6-dimethylhept-2-en-4-ynyl]-ethylamino]methyl]-N-[2-(2-methylphenyl)propan-2-yl]-N-silylaniline Chemical compound C(C)N(C\C=C\C#CC(C)(C)C)CC1=CC(=CC=C1)N(C(C)(C)C1=C(C=CC=C1)C)[SiH3] FYYXCZJXTALUJA-UKTHLTGXSA-N 0.000 description 1
- NZQJEAVBLXFYKK-PKNBQFBNSA-N 3-[[[(E)-6,6-dimethylhept-2-en-4-ynyl]-ethylamino]methyl]-N-[2-(4-methoxyphenyl)propan-2-yl]-N-silylaniline Chemical compound C(C)N(C\C=C\C#CC(C)(C)C)CC1=CC(=CC=C1)N(C(C)(C)C1=CC=C(C=C1)OC)[SiH3] NZQJEAVBLXFYKK-PKNBQFBNSA-N 0.000 description 1
- AKWFOTZUFSSBRJ-CSKARUKUSA-N 3-[[[(e)-6,6-dimethylhept-2-en-4-ynyl]-ethylamino]methyl]-n-ethylaniline Chemical compound CCNC1=CC=CC(CN(CC)C\C=C\C#CC(C)(C)C)=C1 AKWFOTZUFSSBRJ-CSKARUKUSA-N 0.000 description 1
- RLQQOQGHKFQRAM-PKNBQFBNSA-N 4-[2-[3-[[[(E)-6,6-dimethylhept-2-en-4-ynyl]-ethylamino]methyl]phenoxy]propan-2-ylsilyl]-3-methylphenol Chemical compound C(C)N(C\C=C\C#CC(C)(C)C)CC1=CC(=CC=C1)OC([SiH2]C1=C(C=C(C=C1)O)C)(C)C RLQQOQGHKFQRAM-PKNBQFBNSA-N 0.000 description 1
- PKFNIRFNJGZCAO-CSKARUKUSA-N 4-[2-[3-[[[(E)-6,6-dimethylhept-2-en-4-ynyl]-ethylamino]methyl]phenoxy]propan-2-ylsilyl]benzaldehyde Chemical compound C(C)N(C\C=C\C#CC(C)(C)C)CC1=CC(=CC=C1)OC([SiH2]C1=CC=C(C=C1)C=O)(C)C PKFNIRFNJGZCAO-CSKARUKUSA-N 0.000 description 1
- FYCHUVVECOTLTH-CSKARUKUSA-N 4-[2-[3-[[[(E)-6,6-dimethylhept-2-en-4-ynyl]-ethylamino]methyl]phenoxy]propan-2-ylsilyl]phenol Chemical compound C(C)N(C\C=C\C#CC(C)(C)C)CC1=CC(=CC=C1)OC([SiH2]C1=CC=C(C=C1)O)(C)C FYCHUVVECOTLTH-CSKARUKUSA-N 0.000 description 1
- GPIARXZSVWTOMD-UHFFFAOYSA-N 4-[chloro(dimethyl)silyl]butanenitrile Chemical compound C[Si](C)(Cl)CCCC#N GPIARXZSVWTOMD-UHFFFAOYSA-N 0.000 description 1
- JDMRYCIBPFYGQT-UHFFFAOYSA-N 4-[chloromethyl(dimethyl)silyl]-n,n-dimethylaniline Chemical compound CN(C)C1=CC=C([Si](C)(C)CCl)C=C1 JDMRYCIBPFYGQT-UHFFFAOYSA-N 0.000 description 1
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-dimethylaminophenol Chemical compound CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 description 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
- KINKCKZJZMYKGH-FOWTUZBSSA-N 5-[[[(E)-6,6-dimethylhept-2-en-4-ynyl]-ethylamino]methyl]-2-methoxy-N-(3-phenylpentan-3-yl)-N-silylaniline Chemical compound C(C)N(C\C=C\C#CC(C)(C)C)CC1=CC(=C(C=C1)OC)N(C(CC)(CC)C1=CC=CC=C1)[SiH3] KINKCKZJZMYKGH-FOWTUZBSSA-N 0.000 description 1
- BVXNJJWTUNTHCF-UHFFFAOYSA-N 5-chloropent-1-enyl(dimethyl)silane Chemical compound ClCCCC=C[SiH](C)C BVXNJJWTUNTHCF-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- ODXAZUYWTMOFTR-UHFFFAOYSA-N C(C)N(CC=CC#CC(C)(C)C)CC1=CC(=CC=C1)C#N Chemical compound C(C)N(CC=CC#CC(C)(C)C)CC1=CC(=CC=C1)C#N ODXAZUYWTMOFTR-UHFFFAOYSA-N 0.000 description 1
- WILGCKRAFQRLPL-UHFFFAOYSA-N C(C)N(CC=CC#CC(C)(C)C)CC1=CC(=CC=C1)OC([SiH](C)C)C1=CC=C(C=C1)C Chemical compound C(C)N(CC=CC#CC(C)(C)C)CC1=CC(=CC=C1)OC([SiH](C)C)C1=CC=C(C=C1)C WILGCKRAFQRLPL-UHFFFAOYSA-N 0.000 description 1
- QBHKMWKZMRWKOX-PKNBQFBNSA-N C(C)N(C\C=C\C#CC(C)(C)C)CC1=CC(=CC=C1)N(C)C([SiH2]C=1C=NC=CC=1)(C)C Chemical compound C(C)N(C\C=C\C#CC(C)(C)C)CC1=CC(=CC=C1)N(C)C([SiH2]C=1C=NC=CC=1)(C)C QBHKMWKZMRWKOX-PKNBQFBNSA-N 0.000 description 1
- PSXHMWPBUYUOTP-ZRDIBKRKSA-N C(C)N(C\C=C\C#CC(C)(C)C)CC1=CC(=CC=C1)OC([SiH2]C1=CC=C(C=C1)C=C)(C)C Chemical compound C(C)N(C\C=C\C#CC(C)(C)C)CC1=CC(=CC=C1)OC([SiH2]C1=CC=C(C=C1)C=C)(C)C PSXHMWPBUYUOTP-ZRDIBKRKSA-N 0.000 description 1
- ADJMGQCQNNDZQU-CSKARUKUSA-N C(C)N(C\C=C\C#CC(C)(C)C)CC1=CC(=CC=C1)OC([SiH2]C=1C=NC=CC=1)(C)C Chemical compound C(C)N(C\C=C\C#CC(C)(C)C)CC1=CC(=CC=C1)OC([SiH2]C=1C=NC=CC=1)(C)C ADJMGQCQNNDZQU-CSKARUKUSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- AAIJEURQKZASKQ-UHFFFAOYSA-N Cc(cc1C)ccc1F Chemical compound Cc(cc1C)ccc1F AAIJEURQKZASKQ-UHFFFAOYSA-N 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 239000005046 Chlorosilane Substances 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 101000801643 Homo sapiens Retinal-specific phospholipid-transporting ATPase ABCA4 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 102000006835 Lamins Human genes 0.000 description 1
- 108010047294 Lamins Proteins 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- OTKHYVRBIAYADK-PKNBQFBNSA-N N-[2-(4-bromophenyl)silylpropan-2-yl]-3-[[[(E)-6,6-dimethylhept-2-en-4-ynyl]-ethylamino]methyl]-N-methylaniline Chemical compound C(C)N(C\C=C\C#CC(C)(C)C)CC1=CC(=CC=C1)N(C)C([SiH2]C1=CC=C(C=C1)Br)(C)C OTKHYVRBIAYADK-PKNBQFBNSA-N 0.000 description 1
- ONYZBPKRFYSJSG-PKNBQFBNSA-N N-[4-[2-[3-[[[(E)-6,6-dimethylhept-2-en-4-ynyl]-ethylamino]methyl]phenoxy]propan-2-ylsilyl]phenyl]acetamide Chemical compound C(C)N(C\C=C\C#CC(C)(C)C)CC1=CC(=CC=C1)OC([SiH2]C1=CC=C(C=C1)NC(C)=O)(C)C ONYZBPKRFYSJSG-PKNBQFBNSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 102100033617 Retinal-specific phospholipid-transporting ATPase ABCA4 Human genes 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 238000006859 Swern oxidation reaction Methods 0.000 description 1
- STSCVKRWJPWALQ-UHFFFAOYSA-N TRIFLUOROACETIC ACID ETHYL ESTER Chemical compound CCOC(=O)C(F)(F)F STSCVKRWJPWALQ-UHFFFAOYSA-N 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229910009257 Y—Si Inorganic materials 0.000 description 1
- UKWRSXOKBHFHTQ-UHFFFAOYSA-N [3-(bromomethyl)phenoxy]-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OC1=CC=CC(CBr)=C1 UKWRSXOKBHFHTQ-UHFFFAOYSA-N 0.000 description 1
- YHVSRWZQNUAQPS-UHFFFAOYSA-N [4-(chloromethylsulfanylmethyl)phenyl]-dimethylsilane Chemical compound ClCSCC1=CC=C(C=C1)[SiH](C)C YHVSRWZQNUAQPS-UHFFFAOYSA-N 0.000 description 1
- KOOADCGQJDGAGA-UHFFFAOYSA-N [amino(dimethyl)silyl]methane Chemical compound C[Si](C)(C)N KOOADCGQJDGAGA-UHFFFAOYSA-N 0.000 description 1
- XXFXTBNFFMQVKJ-UHFFFAOYSA-N [diphenyl(trityloxy)methyl]benzene Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)OC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 XXFXTBNFFMQVKJ-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- DCBDOYDVQJVXOH-UHFFFAOYSA-N azane;1h-indole Chemical compound N.C1=CC=C2NC=CC2=C1 DCBDOYDVQJVXOH-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000003935 benzaldehydes Chemical class 0.000 description 1
- ABHNFDUSOVXXOA-UHFFFAOYSA-N benzyl-chloro-dimethylsilane Chemical compound C[Si](C)(Cl)CC1=CC=CC=C1 ABHNFDUSOVXXOA-UHFFFAOYSA-N 0.000 description 1
- XKXHCNPAFAXVRZ-UHFFFAOYSA-N benzylazanium;chloride Chemical compound [Cl-].[NH3+]CC1=CC=CC=C1 XKXHCNPAFAXVRZ-UHFFFAOYSA-N 0.000 description 1
- 125000001743 benzylic group Chemical group 0.000 description 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 201000002676 cerebral atherosclerosis Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- XJHCXCQVJFPJIK-UHFFFAOYSA-M cesium fluoride Substances [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 1
- AJNRYMFTFNZMSH-UHFFFAOYSA-N chloro-(2,6-dimethylphenyl)-dimethylsilane Chemical compound CC1=CC=CC(C)=C1[Si](C)(C)Cl AJNRYMFTFNZMSH-UHFFFAOYSA-N 0.000 description 1
- MEUXNEGJODESOX-UHFFFAOYSA-N chloro-cyclohexyl-dimethylsilane Chemical compound C[Si](C)(Cl)C1CCCCC1 MEUXNEGJODESOX-UHFFFAOYSA-N 0.000 description 1
- VIJZFXJTHHFAIO-UHFFFAOYSA-N chloro-dimethyl-(2-methylphenyl)silane Chemical compound CC1=CC=CC=C1[Si](C)(C)Cl VIJZFXJTHHFAIO-UHFFFAOYSA-N 0.000 description 1
- HXSJCLYCJZBHFZ-UHFFFAOYSA-N chloro-dimethyl-pyridin-3-ylsilane Chemical compound C[Si](C)(Cl)C1=CC=CN=C1 HXSJCLYCJZBHFZ-UHFFFAOYSA-N 0.000 description 1
- DEPVFYAOAUKMFL-UHFFFAOYSA-N chloro-dimethyl-thiophen-2-ylsilane Chemical compound C[Si](C)(Cl)C1=CC=CS1 DEPVFYAOAUKMFL-UHFFFAOYSA-N 0.000 description 1
- TZMFQNADFMIXQK-UHFFFAOYSA-N chloro-dimethyl-thiophen-3-ylsilane Chemical compound C[Si](C)(Cl)C=1C=CSC=1 TZMFQNADFMIXQK-UHFFFAOYSA-N 0.000 description 1
- IPAIXTZQWAGRPZ-UHFFFAOYSA-N chloro-methyl-phenylsilicon Chemical compound C[Si](Cl)C1=CC=CC=C1 IPAIXTZQWAGRPZ-UHFFFAOYSA-N 0.000 description 1
- OOCUOKHIVGWCTJ-UHFFFAOYSA-N chloromethyl(trimethyl)silane Chemical compound C[Si](C)(C)CCl OOCUOKHIVGWCTJ-UHFFFAOYSA-N 0.000 description 1
- IJJIRXWFFHCIIA-UHFFFAOYSA-N chloromethyl-(2-ethylphenyl)-dimethylsilane Chemical compound CCC1=CC=CC=C1[Si](C)(C)CCl IJJIRXWFFHCIIA-UHFFFAOYSA-N 0.000 description 1
- GWZIEVDUMGBXHM-UHFFFAOYSA-N chloromethyl-(2-methoxyphenyl)-dimethylsilane Chemical compound COC1=CC=CC=C1[Si](C)(C)CCl GWZIEVDUMGBXHM-UHFFFAOYSA-N 0.000 description 1
- NKWCDCKUPVEDRZ-UHFFFAOYSA-N chloromethyl-(3,4-dimethylphenyl)-dimethylsilane Chemical compound ClC[Si](C)(C)C1=CC(=C(C=C1)C)C NKWCDCKUPVEDRZ-UHFFFAOYSA-N 0.000 description 1
- FWDXLPVOTHYLAA-UHFFFAOYSA-N chloromethyl-(4-chlorophenyl)-dimethylsilane Chemical compound ClC[Si](C)(C)C1=CC=C(Cl)C=C1 FWDXLPVOTHYLAA-UHFFFAOYSA-N 0.000 description 1
- ZZWQHOCSRVUZBY-UHFFFAOYSA-N chloromethyl-(4-fluoro-3-methylphenyl)-dimethylsilane Chemical compound CC1=CC([Si](C)(C)CCl)=CC=C1F ZZWQHOCSRVUZBY-UHFFFAOYSA-N 0.000 description 1
- XSJVEAYUPCYJFC-UHFFFAOYSA-N chloromethyl-dimethyl-(3-methylphenyl)silane Chemical compound CC1=CC=CC([Si](C)(C)CCl)=C1 XSJVEAYUPCYJFC-UHFFFAOYSA-N 0.000 description 1
- MBVPERNHUDOZTD-UHFFFAOYSA-N chloromethyl-dimethyl-(3-phenylphenyl)silane Chemical compound ClC[Si](C)(C)C1=CC=CC(C=2C=CC=CC=2)=C1 MBVPERNHUDOZTD-UHFFFAOYSA-N 0.000 description 1
- OCERXZWFJLUJQO-UHFFFAOYSA-N chloromethyl-dimethyl-(4-methylphenyl)silane Chemical compound CC1=CC=C([Si](C)(C)CCl)C=C1 OCERXZWFJLUJQO-UHFFFAOYSA-N 0.000 description 1
- NODYWLVSRLVQPF-UHFFFAOYSA-N chloromethyl-dimethyl-(4-phenylphenyl)silane Chemical compound C1=CC([Si](C)(CCl)C)=CC=C1C1=CC=CC=C1 NODYWLVSRLVQPF-UHFFFAOYSA-N 0.000 description 1
- WBZTYASEAQTKBK-UHFFFAOYSA-N chloromethyl-dimethyl-(trimethylsilylmethyl)silane Chemical compound C[Si](C)(C)C[Si](C)(C)CCl WBZTYASEAQTKBK-UHFFFAOYSA-N 0.000 description 1
- DLMVMDSJYYOHBZ-UHFFFAOYSA-N chloromethyl-dimethyl-[2-(trifluoromethyl)phenyl]silane Chemical compound ClC[Si](C)(C)C1=CC=CC=C1C(F)(F)F DLMVMDSJYYOHBZ-UHFFFAOYSA-N 0.000 description 1
- BHTQXWYXSLABAB-UHFFFAOYSA-N chloromethyl-dimethyl-[4-(trifluoromethoxy)phenyl]silane Chemical compound ClC[Si](C)(C)C1=CC=C(OC(F)(F)F)C=C1 BHTQXWYXSLABAB-UHFFFAOYSA-N 0.000 description 1
- ZTCVORYIVOIROB-UHFFFAOYSA-N chloromethyl-dimethyl-naphthalen-1-ylsilane Chemical compound C1=CC=C2C([Si](C)(CCl)C)=CC=CC2=C1 ZTCVORYIVOIROB-UHFFFAOYSA-N 0.000 description 1
- YROJGFUEFVWIMV-UHFFFAOYSA-N chloromethyl-dimethyl-naphthalen-2-ylsilane Chemical compound C1=CC=CC2=CC([Si](C)(CCl)C)=CC=C21 YROJGFUEFVWIMV-UHFFFAOYSA-N 0.000 description 1
- DBSKUBRYORPTQH-UHFFFAOYSA-N chloromethyl-dimethyl-pyridin-3-ylsilane Chemical compound ClC[Si](C)(C)C1=CC=CN=C1 DBSKUBRYORPTQH-UHFFFAOYSA-N 0.000 description 1
- SZZZMXFBEKWPBU-UHFFFAOYSA-N chloromethyl-ethenyl-dimethylsilane Chemical compound ClC[Si](C)(C)C=C SZZZMXFBEKWPBU-UHFFFAOYSA-N 0.000 description 1
- SSQOSTRUDOUBJZ-UHFFFAOYSA-N chloromethyl-methyl-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](CCl)(C)C1=CC=CC=C1 SSQOSTRUDOUBJZ-UHFFFAOYSA-N 0.000 description 1
- KOPOQZFJUQMUML-UHFFFAOYSA-N chlorosilane Chemical compound Cl[SiH3] KOPOQZFJUQMUML-UHFFFAOYSA-N 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229960003280 cupric chloride Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- UBHZUDXTHNMNLD-UHFFFAOYSA-N dimethylsilane Chemical compound C[SiH2]C UBHZUDXTHNMNLD-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 150000002031 dolichols Chemical class 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 108010017796 epoxidase Proteins 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- BADWIIDKTXQYLW-UHFFFAOYSA-N ethenylstannane Chemical compound [SnH3]C=C BADWIIDKTXQYLW-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 125000002686 geranylgeranyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- YPGCWEMNNLXISK-UHFFFAOYSA-N hydratropic acid Chemical compound OC(=O)C(C)C1=CC=CC=C1 YPGCWEMNNLXISK-UHFFFAOYSA-N 0.000 description 1
- 238000006197 hydroboration reaction Methods 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- NIZHERJWXFHGGU-UHFFFAOYSA-N isocyanato(trimethyl)silane Chemical compound C[Si](C)(C)N=C=O NIZHERJWXFHGGU-UHFFFAOYSA-N 0.000 description 1
- ULYZAYCEDJDHCC-UHFFFAOYSA-N isopropyl chloride Chemical compound CC(C)Cl ULYZAYCEDJDHCC-UHFFFAOYSA-N 0.000 description 1
- 210000005053 lamin Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- UIDWHMKSOZZDAV-UHFFFAOYSA-N lithium tin Chemical group [Li].[Sn] UIDWHMKSOZZDAV-UHFFFAOYSA-N 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 1
- KMFJVYMFCAIRAN-UHFFFAOYSA-N methyl 3-bromobenzoate Chemical compound COC(=O)C1=CC=CC(Br)=C1 KMFJVYMFCAIRAN-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- IZIOYSKLCVTHDH-UHFFFAOYSA-N n-(3-cyano-4-methoxyphenyl)-2,2,2-trifluoroacetamide Chemical compound COC1=CC=C(NC(=O)C(F)(F)F)C=C1C#N IZIOYSKLCVTHDH-UHFFFAOYSA-N 0.000 description 1
- BRHNLNBFECGZQB-UHFFFAOYSA-N n-[dimethyl(phenyl)silyl]-3-(ethylaminomethyl)-n-methylaniline Chemical compound CCNCC1=CC=CC(N(C)[Si](C)(C)C=2C=CC=CC=2)=C1 BRHNLNBFECGZQB-UHFFFAOYSA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001979 organolithium group Chemical group 0.000 description 1
- 125000002734 organomagnesium group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 150000003139 primary aliphatic amines Chemical class 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- JKANAVGODYYCQF-UHFFFAOYSA-N prop-2-yn-1-amine Chemical compound NCC#C JKANAVGODYYCQF-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 150000003421 squalenes Chemical class 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 108010003641 statine renin inhibitory peptide Proteins 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- QNMBSXGYAQZCTN-UHFFFAOYSA-N thiophen-3-ylboronic acid Chemical compound OB(O)C=1C=CSC=1 QNMBSXGYAQZCTN-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- QIWRFOJWQSSRJZ-UHFFFAOYSA-N tributyl(ethenyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C=C QIWRFOJWQSSRJZ-UHFFFAOYSA-N 0.000 description 1
- XEKIDGIZQAEOKB-UHFFFAOYSA-N tributyl(iodomethyl)stannane Chemical compound CCCC[Sn](CI)(CCCC)CCCC XEKIDGIZQAEOKB-UHFFFAOYSA-N 0.000 description 1
- WRECIMRULFAWHA-UHFFFAOYSA-N trimethyl borate Chemical compound COB(OC)OC WRECIMRULFAWHA-UHFFFAOYSA-N 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- AALQBIFJJJPDHJ-UHFFFAOYSA-K trisodium;thiophosphate;dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[O-]P([O-])([O-])=S AALQBIFJJJPDHJ-UHFFFAOYSA-K 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the subject of the present invention is new derivatives of
- Atherosclerosis is a degenerative arterial disease that causes many coronary arterial diseases and
- Atherosclerosis begins with a deposit of lipid in the wall of the vessels and leads to clinical symptoms such as cardiac ischemia, myocardial infarction, angina pectoris or
- cholesterol comes from de novo biosynthesis.
- HMGCo-A-reductase are used as therapeutic agents
- the inhibitors of this enzyme are also capable of inhibiting the formation of other important biological metabolites such as dolichol, 1 ubiquinone, 1 isopentenyl adenine or farnesylated or geranyl-geranyl proteins.
- Inhibitors of squalene epoxidase should make it possible to avoid these problems while keeping a very good cholesterol-lowering activity.
- Some compounds have been described as inhibitors of squalene epoxidase of fungal origin such as certain allyl-benzylamines (naftifine or terbinafine, NS Ryder, Biochem. Soc. Trans., 1 £, 774-777, 1991) and of squalene epoxidase such as squalene derivatives (Chemtracts-Org. Chem. 5_, 27-30, 1992; Prestwich et al. J. Am. Chem. Soc. 11. 9674-9675, 1991;. Moore et al. J. Am. Chem. Soc. 114. 360-361, 1992, W. Von Sic le, Lipids, 22 ..
- the compounds according to the present invention are potent inhibitors of squalene epoxidase and / or antioxidants capable of protecting LDL from oxidative modifications.
- the derivatives of the present invention alone or combined with other therapeutic agents find their utility as medicaments and more particularly for the treatment and prevention of hypercholesterolemia, hyperlipemia, atherosclerosis, diseases linked to deficiency or any abnormality in the LDL receptors, but also pathologies in which peroxidation or any other form of lipid oxidation play an initiating and / or aggravating role, such as ischemical heart disease,. reperfusion of organs, including transplants, traumatic or degenerative ischemical pathologies of the central or peripheral nervous system, acute or chronic inflammatory diseases, autoimmune diseases and metabolic diseases such as " for example diabetes.
- the present invention relates to silylated benzylamine derivatives corresponding to formula I
- R 1 represents a hydrogen atom, a hydrocarbon radical containing from 1 to 5 carbon atoms in a straight or branched chain, or a cycloalkyl comprising from 3 to 7 carbon atoms.
- R2 represents a hydrocarbon radical containing from 1 to 6 carbon atoms in a straight or branched chain optionally substituted with a methoxy or ethoxy radical, or a trimethylsilylated or triethylsilylated residue.
- R3 represents a hydrogen, fluorine, chlorine or bromine atom, a hydrocarbon radical containing from 1 to 6 carbon atoms in a straight or branched chain, a hydroxy, thio, acyloxy (R'3CO2) alkoxy (R 'radical) 3 ⁇ ) or alkylthio (R'3S) in which R'3 is a branched or linear hydrocarbon radical containing from 1 to 6 carbon atoms.
- R4 and R5 identical or different, each represent a hydrogen, a branched or linear hydrocarbon radical containing from 1 to 6 carbon atoms, a cycloalkyl residue containing from 3 to 8 carbon atoms or an aryl residue such as a phenyl.
- R6 represents a linear or branched hydrocarbon radical containing from 1 to 6 carbon atoms, a cycloalkyl comprising from 3 to 8 carbon atoms or an aryl (such as phenyl, naphthyl, thienyl, furan, pyrrole, pyridine, imidazole, triazole , thiazole, oxazole) which may be substituted by one or more of the groups chosen from a hydrocarbon radical containing from 1 to 6 carbon atoms (optionally containing a double or a triple bond and which may be variously substituted), a hydroxyl (OH), a ether (OR 1 6) an amine (NH2, NHR'6 or R'6R M 6) 'an amine derivative (NHCOR'6, NHC02R'6>NHCONR'6R"6 or NHS02R'6)' an acyl ( OCOR '6) .a carbonyl (COH, COR' ⁇ > , C02R'6
- n 0, or an integer between 1 and 5.
- n an integer between 1 and 5.
- X represents an oxygen or sulfur atom or an NR7 radical.
- R7 represents a hydrogen, a linear or branched alk chain comprising from 1 to 6 carbon atoms, an acyl radical (COR 1 7) in which R'7 represents a linear or branched alkyl chain comprising from 1 to 6 carbon atoms, an aryl radical such as a phenyl, or a trifluoromethyl radical.
- Z represents a linear or branched hydrocarbon radical comprising from 2 to 6 carbon atoms, a triple bond (CC), a double bond (Z'CH ⁇ CHZ ") of stereochemistry Z or E in which Z 'and Z" identical or different represent a hydrogen atom, a fluorine atom, or a linear or branched hydrocarbon radical comprising from 1 to 6 carbon atoms.
- the compounds of formula (I) containing one or more asymmetric centers have isomeric forms.
- the racemates and pure enantiomers of. these compounds are also part of this invention.
- the invention also includes the salts, solvates (eg, hydrates) and bioprecursors of these compounds acceptable for therapeutic use.
- salts acceptable for the therapeutic use of the benzylamines of formula (I) mention will be made of the salts formed by addition with organic or mineral acids and for example the hydrochlorides, hydrobromides, sulfates, fumarates, tartrates and maleates.
- bioprecursors as used in the present invention applies to compounds of formula (I), but which, when administered to an animal or to a human being, are converted in the body into a compound of formula (I).
- the present invention describes a new class of silylated benzylamine derivatives which differs from the closest derivatives of the prior art not only by their original chemical structure but also by their biological profile and their therapeutic application since the compounds according to the present invention find their main and non-exclusive use as cholesterol lowering agents and / or antioxidants.
- the present invention also relates to the process for the preparation of derivatives of general formula (I) characterized in that a derivative of general formula (II) is condensed
- R4, R5, R ⁇ and n are defined as above and Y is a leaving group, which can be a halogen (bromine, chlorine or iodine), or an alcohol derivative (mesylate, tosylate, triflate).
- halogen bromine, chlorine or iodine
- alcohol derivative mesylate, tosylate, triflate
- the benzylamines of formula (II) are preferably condensed with a silylated derivative of formula (III) in which Y is a chlorine or bromine atom, in a polar and aprotic solvent such as dimethylformamide (DMF), tetrahydrofuran (THF) or DMSO, at a temperature between 50 and 100 ° C (in the presence of a catalytic or stoichiometric amount of potassium iodide if Y is a chlorine atom or a mesylate radical) in the presence of a base such as potassium carbonate, cesium carbonate, sodium hydride, a tertiary amine (N-methylmorpholine, di-isopropylethylamine, dimethyl-aminopyridine) or potassium t-butoxide.
- a polar and aprotic solvent such as dimethylformamide (DMF), tetrahydrofuran (THF) or DMSO
- an agent capable of regenerating the free amine such as KOH, NaOH, sodium methylate or ethylate , ammonia in a polar protic solvent such as methanol, ethanol or isopropanol.
- the condensation of the intermediates (II 1 ) and (III ') to lead to the derivatives of general formula (I) is carried out under the usual conditions to carry out this type of nucleophilic substitution.
- This is how this condensation can be carried out in a polar solvent such as DME, DMF, THF, DMSO, sulfolone, at a temperature between 20 and 120 * C (preferably between 40 and 80 * C) in the presence of an organic base (NaH, KH, Et3N, DBU, DBN, DiPEA, t ⁇ uOK) or inorganic (K2CO3, KHCO3, NaHC03, CS2C03, KOH, NaOH, ).
- a polar solvent such as DME, DMF, THF, DMSO, sulfolone
- R3 and m are defined as in the general formula (I)
- Y is a leaving group such as a halogen (bromine, chlorine, iodine), a mesylate, triflate or tosylate
- X ′ may be equivalent to X or X 'is a function which is a precursor of X and which can be transformed into X as defined in formula (I), during a subsequent step
- R3 is defined as in formula I and R 'is a linear hydrogen-carbon radical comprising from 1 to 4 carbon atoms (preferably a methyl radical) followed by the reduction of the ester function with a reducing agent well known for the transformation of an ester of primary alcohol, such as boron or aluminum hydrides, a preferred method being the use of aluminum hydrides such as diisobutylaluminum hydride or LiAlH4.
- the intermediate (IVe) is itself obtained from m-thio-cresol, by initial protection of the thiol function as described in T.W. Greene, Protective Groups in Organic Synthesis, John Wiley &. Sons, N.Y., 1981, followed by benzyl bromination using N-bromosuccinimide in CCI4.
- the intermediates of general formula (II) in which m is non-zero and X is a sulfur atom are preferably prepared from the intermediates of general formula (II) in which m is non-zero and X is an atom of oxygen, by initial transformation of the alcohol into a good leaving group (this is how the alcohol can be transformed into bromine after reaction with HBr, PBr3, (CBr4-P3) or Br2 ⁇ P3, into mesylate after reaction with mesyl chloride in the presence of pyridine / in triflate after reaction with triflic anhydride in the presence of pyridine or in tosylate after reaction with tosyl chloride in the presence of pyridine under the temperature conditions and solvents well known for this type of transformation ) followed by a reaction with R8C (0) SM in which R8 is methyl or phenyl and M a metal such as sodium or potassium followed by hydrolysis of the thioester with sodium ethylate in ethanol.
- the intermediates of general formula (II) are prepared by condensation of an amine of general formula (V) with a compound of general formula (IV) in which Y is a good leaving group such as bromine or mesylate, m 2 and X 'is a protected form of an alcohol such as a silyl ether, a trityl ether, or a tetrahydropyrannical ether, followed by deprotection of' function alcohol which will be dependent on the protective group chosen (cf. TW Greene, Protective Groups in Organic Synthesis, John Wiley & _ Sons, NY, 1981).
- silylated derivatives of general formula (III) in which R4, R5, R6 and n are described as above and Y is a good leaving group such as a halogen (chlorine, bromine or iodine) or an alcohol derivative such as a mesylate, a triflate or a tosylate are prepared by various methods and techniques well known to those skilled in the art.
- a good leaving group such as a halogen (chlorine, bromine or iodine) or an alcohol derivative such as a mesylate, a triflate or a tosylate.
- silylated intermediates (III ') in which R4, R5, R ⁇ , X and n are defined as above are obtained by different methods well known to those skilled in the art and which depend both on the nature of the substituents on the atom of silicon, of the nature of n and of X.
- the derivatives of formula (III ") in which X represents an oxygen can be prepared by reduction of a carbonyl derivative such as an acid, an ester or an aldehyde by well known methods such as the use of aluminum or boron hydrides, preferably LiAlH4, DiBAl-H or BH3, or also by hydroborations / oxidation of unsaturated silanes according to the methods and techniques well known for this type of reaction (cf. J. Am. Chem. Soc. 100. 5534, 1978) or also by condensation of an organomagnesium (VI)
- PG represents an appropriate protective group such as a benzyl, a tbutyldimethylsilyl, a trityl or a tetrahydropyranyl and n is between 1 and 5, with an appropriate chlorosilane (ClSiR4R5R6) followed by deprotection of the alcohol function by an adequate method linked to the nature of the protecting group (cf. TW Greene,
- Silylated intermediates (III ') can also be prepared from silylated intermediates
- the derivatives (III ') in which X is an oxygen can be prepared by reaction of an intermediate (III) with the potassium acetate followed by reduction with LiAlH4.
- the derivatives (III 1 ) in which X is a sulfur can be prepared by reaction of an intermediate (III) with potassium thioacetate followed by the release of the thiol by reaction with sodium methylate in methanol.
- the derivatives (III 1 ) in which X is a nitrogen can be obtained after reaction of the intermediates (III) with NaN3 or potassium phthalimide followed by the transformation of the intermediate into an amine, whether by reduction with NaBH4 or treatment with triphenylphosphine and hydrolysis when the intermediate is an azide or treatment with hydrazine hydrated in ethanol when the intermediate is a phthalimide.
- a method also appreciated for the preparation of silylated intermediates of formula (III) consists in treating intermediates of formula (III ') in which " X is an oxygen by the techniques and methods which make it possible to transform an alcohol into a good leaving group.
- the amines of general formula (V) are prepared by various methods well known to those skilled in the art and which are adapted from reactions used in the chemistry of acetylenes as described in Brandsma, L. Preparative acetylenic chemistry (studies in organic chemistry, vol. 34) 2 n ⁇ Ed., Elsevier, Amsterdam, 1988. Some examples of the methods used depending on the nature of Z are described here. In the particular cases where Z is a double bond, the amines of general formula (V) can be prepared by the methods and techniques described in J. Med. Chem. 21, 1539 (1984), Tetrahedron, H, 5685 (1985), Tetrahedron Lett. 3145 (1989), Tetrahedron Lett. 21, 1509 (1989), J. Med. Chem. , 65-73 (1991) and Pestic. Sci. 3_1, 437 (1991) as well as in European patent application 0 421 302 A2.
- the amines of general formula (V) can be prepared by the well-known method which consists in condensing a terminal acetylene derivative with a bromo-1-acetylene in the presence of chloride or iodide copper (I) and NH20H [cf. Proc. Chem. Soc, 340 (1963), Tetrahedron Lett., 1953 (1965), Synthesis, 2, 230 (1984), C.R. Acad. Sci. 2 ⁇ 1, 215 (1965)] or in the presence of palladium and Cul in THF [cf. Synth. Common. 21, 977 (1991)].
- the amines of general formula (V) in which Z is a triple bond are preferably prepared by condensation of an acetylene derivative of general formula (VII), according to the methods described above,
- the amines of general formula (V) in which Z is an acetylene can also be prepared by the same type of methods and techniques but by condensing an acetylenic bromide of structure (IX) with a terminal acetylene derivative of structure (X)
- the amines of general formula (V) in which Z represents a linear or branched hydrogen-carbon radical comprising from 2 to 4 carbon atoms are generally prepared by transformation of an intermediate alcohol (XI) in which
- n is between 2 and 4 as the desired amine, for example by nucleophilic substitution of the mesylate or of the alcohol-derived triflate with sodium azide or potassium phthalimide followed by a transformation of the intermediate (azide or phthalimide) to the amine by the methods described above.
- R ' is an alkyl or a phenyl with a propargyl bromide (R2CC-CH2Br) in which R2 is described as above in the presence of the sodium salt of hexamethyldisilazane [cf. Tetrahedron Asymm. , 2., 105
- a reducing agent such as LiAlH4.
- Aldehydes (XIII) can be prepared either by oxidation of the corresponding alcohols (which have been described above) by methods such as the Swern oxidation, the use of PDC or even tetrapropyl perruthenate, or by reduction of the corresponding esters (in particular the methyl or ethyl esters) in toluene thanks to di-isobutylaluminum hydride.
- a particularly appreciated alternative method for preparing the compounds of general formula (I) consists in preparing an intermediate benzaldehyde of general formula (XIV):
- An alternative and particularly appreciated method consists in carrying out a reductive amination between the aldehyde of formula (XIV) with a primary amine of formula R1NH2 and in condensing the benzylamine of formula (XV) thus formed.
- This condensation reaction of the benzylamines of formula (XV) with the electrophiles of formula (XVI) can be carried out in the presence of an inorganic or organic base (NaH, KH, DIPEA, DMAP, DBU, K2CO3, CS2CO3) in an anhydrous solvent polar such as THF, DMF, DME, DMSO, at a temperature between 20 and 80 "C.
- an inorganic or organic base NaH, KH, DIPEA, DMAP, DBU, K2CO3, CS2CO3
- an anhydrous solvent polar such as THF, DMF, DME, DMSO
- m, X and R3 are defined as above with a silylated derivative of general formula (III) described as above (according to the techniques and methods previously described during the condensation between (II) and (III), followed by the controlled reduction of the nitrile function to the aldehyde by reducing agents well known to those skilled in the art for this type of transformation such as for example diisobutylaluminum hydride (DiBAl-H) in solvents such as hexane, THF or toluene to temperatures between -78'C and -20'C followed by a step of hydrolysis in dilute acid medium at a temperature between O'C and 40'C.
- DiBAl-H diisobutylaluminum hydride
- Y represents a leaving group such as chlorine, bromine or iodine.
- Y is a bearing group such as chlorine, bromine or iodine and which can be prepared according to the methods well known in the literature (Ahman, J.; Somfai, P. Synth. Commun. 1994, 2, 1117- 1120)
- a derivative of formula (I) in which Ri represents a hydrocarbon radical and X is different from NH can be prepared from a derivative of formula (I) in which Ri represents a hydrogen (and X is different from NH) by alkylation with an alkyl halide in basic medium or by condensation with an aldehyde followed by a reduction step according to the method known as "reductive amination”.
- a derivative of formula (I) in which R3 is an acyloxy (R'3CO2) or alkoxy (R'30) by suitable well-known methods for converting a phenol ester or ether into phenol.
- a derivative of formula (I) in which R6 represents an aromatic substituted by a bromine atom can be transformed into another derivative of formula (I) in which the aromatic is substituted in the same position by a hydroxyl, a thiol, an amine, a trimethylsilyl, an alkyl which can be variously substituted, a carbonyl, (CHO, COR ' ⁇ , COOR'6 / CONHR' 6), a trifluoroacetyl, a nitrile, an aryl (such as a phenyl, ...), a vinyl or an acetylene which can be variously substituted.
- Certain transformations can be carried out by reaction at low temperature of such an aromatic bromine of formula (I) with an organolithian such as butyllithium (primary, secondary or tertiary) in an anhydrous solvent such as ether or THF, at a temperature included between - 100'C and - 50'C, followed by condensation with an appropriate electrophile (Sniekus, V. Chem. Rev. 1990, 90. 879-933) at low temperature (-50'C to -100 * 0.
- organolithian such as butyllithium (primary, secondary or tertiary) in an anhydrous solvent such as ether or THF
- the intermediate lithian is treated with a boronate [B (OR) 3] which is then preferentially oxidized by oxidants such as hydrogen peroxide or N-methyl morpholine- N-oxide at one, temperature between 20 "C and 80'C
- oxidants such as hydrogen peroxide or N-methyl morpholine- N-oxide at one, temperature between 20 "C and 80'C
- the intermediate boronate can also be transformed into boronic acid by acid hydrolysis and then condensed with a bromine derivative or an aromatic or heteromatic triflate in the presence of a palladium catalyst according to the method well known by the name of Suzuki coupling (Sniekus, V. et al. J. Org. Chem., 5 £, 3763, 1991).
- the derivatives of general formula (I) in which R6 represents an aromatic substituted by a nitrile (CN) can also be prepared from the corresponding aromatic bromine derivatives by coupling the latter with a cyanide salt in the presence of copper (I) or palladium.
- a compound according to the invention in the form of a salt, for example in the form of a salt formed by addition with an acid
- this can be achieved by treating the free base of general formula (I) with an appropriate acid, preferably in equivalent amount, or by creatinine sulfate in an appropriate solvent.
- the new compounds of general formula (I) When the new compounds of general formula (I) have one or more asymmetric centers, they can be prepared in the form of a racemic mixture or in the form of enantiomers, either by enantioselective synthesis or by resolution.
- the compounds of formula (I) having at least one asymmetric center can for example be separated into their enantiomers by the usual techniques such as the formation of diastereomeric pairs by formation of a salt with an optically active acid such as the acid (- ) di-p-toluoyl- 1-tartaric acid (+) di-p-toluoyl-1-tartaric acid (+) camphor sulfonic acid (()) camphor sulfonic acid (+ ) phenylpropionic, (-) - phenylpropionic acid, followed by fractional crystallization and regeneration of the free base.
- the compounds of formula (I) in which R6 is a hydrogen comprising at least one asymmetric center can also be resolved by formation of diastereomeric amides which are separated by chromatography and hydrolysed to release the chiral auxiliary.
- the compounds of formula (I) can be purified by the usual methods, for example by crystallization (in particular when the compounds of formula (I) are isolated in the form of a salt), chromatography or extraction.
- the resulting medium was then stirred for 5 hours at 90 ° C then diluted with 150 ml of ethyl acetate and hydrolyzed with 50 ml of water are added.
- the organic phase is again washed with 2 x 50 ml of water and then the combined aqueous phases extracted with 100 ml of ethyl acetate.
- the combined organic phases are dried over magnesium sulphate then filtered and evaporated.
- Example D Synthesis of (E) -N-ethyl-N- (6,6-dimethyl-2-hepten-4-ynyl) -3- (vinyldimethylsilylmethoxy) benzylamine ID
- This compound is obtained from (E) -N-ethyl-N- (6,6-dimethyl-2-hepten-4-ynyl) -3-hydroxybenzylamine (HA) (500 mg; 1.84 mmol) and ( chloromethyl) - (1,1 '-biphenyl-4-yl) dimethylsilane (720 mg; 2.76 mmol; 1.5 eq.) according to the procedure used for the preparation of IA-
- Flash purification of the oil obtained on a silica column (90/10 Hexane / Ethyl ether) makes it possible to obtain, in the majority fraction, the expected product in the form of a light yellow oil (519 mg; 65%).
- Flash purification of the oil obtained on a silica column (95/05 Hexane / Ethyl ether) makes it possible to obtain, in the majority fraction, the expected product in the form of a light yellow oil (555 mg; 70%).
- This compound is obtained from (E) -N-ethyl-N- (6,6-dimethyl-2-hepten-4-ynyl) -3-hydroxybenzylamine (IIA) (500 mg; 1.84 mmol) and of (chloromethyl) (4-methoxyphenyl) dimethylsilane (593 mg; 2.76mmol; 1.5 eq.) according to the procedure used for the preparation of IA-
- Flash purification of the oil obtained on a silica column (90/10 petroleum ether / ethyl ether) allows the expected product to be obtained in the majority fraction in the form of a light yellow oil (469 mg; 57% ).
- Example L S y n t h è s e d e 1 a
- Flash purification of the oil obtained on a silica column (90/10 / 0.5 Hexane / Ethyl acetate / Triethylamine) makes it possible to obtain, in the majority fraction, the expected product in the form of a light yellow oil ( 7.9g; 81%).
- nitrile IIIo (4 g, 14.3 mmol) in 50 ml of tetrahydrofuran and maintained at O'C is added DiBAl-H (Aldrich, 1.0 M in toluene, 28.6 ml, 28.6 mmol, 2 eq.). The resulting solution is stirred for 3 hours at room temperature. 15 ml of 5N hydrochloric acid are then added and the medium vigorously stirred for approximately 2 hours. The aqueous phase is brought back to basic pH with concentrated sodium hydroxide and then extracted with ethyl acetate. The organic phase is then washed with water and then dried over magnesium sulfate, filtered and evaporated.
- DiBAl-H Aldrich, 1.0 M in toluene, 28.6 ml, 28.6 mmol, 2 eq.
- IO can also be prepared by. action of potassium carbonate (310mg; 2.24mrnoles; 4eq.) and potassium iodide (140mg; 0.84mmoles; 1.5eq.) on a solution of amine IIIo (160 m g; 0.56mmoles) and
- a solution of N-trifluoroacetyl- (3-cyano) -aniline (12 g, 56 mmol) in 100 ml of anhydrous dimethyl formamide is added dropwise to a suspension of sodium hydride (67 mmol, 2.7 g of a 60% suspension in oil (which is previously washed with dry hexane) in 100 ml of DMF at O'C.
- the reaction medium is stirred for 1 hour at 20 ° C. then the chloromethyl-phenyl-dimethyl-silane (15.6 g, 84 mmol) is added to the reaction medium which is stirred at 90 ° C. for 16 hours, then brought back to 20 ° C. and diluted with 500 ml of ether and washed with water.
- the organic phase is dried over magnesium sulfate, filtered and evaporated.
- the resulting solution is stirred for 3 hours at room temperature. 15 ml of 5N hydrochloric acid are then added and the medium vigorously stirred for approximately 2 hours.
- the aqueous phase is brought back to basic pH with concentrated sodium hydroxide and then extracted with ethyl acetate. The organic phase is then washed with water and then dried over magnesium sulfate, filtered and evaporated.
- the medium is stirred for 2 hours at -10 ° C. then the resulting solution is diluted in ethyl ether and washed with water until neutral pH. The organic phase is then dried over magnesium sulfate, filtered and evaporated.
- lg is prepared according to the same operating procedures (R3, R4, R5, R7) used for the synthesis of IR except that chloromethyl- [(2-methyl) -phenyl] -dimethyl-silane replaces the silane used in the operating mode R3 .
- I is prepared according to the same operating procedures (R3, R4, R5, R7) used for the synthesis of IR except that N- formy1- (3 -cyano) -aniline replaces N-trifluoroacetyl- (3-cyano) -aniline used in procedure R3.
- Iy is prepared according to the same operating procedures (R3, R4, R5, R7) used for the synthesis of IR except that chloromethyl- (4-bromo-phenyl) -dimethyl-silane and N-formyl- (3-cyano) -aniline replace respectively the silane and the aniline used in the procedure R3.
- Iw is prepared according to the operating procedure R6 used for the synthesis of IR except that chloromethyl- (2-cyano-phenyl) -dimethyl-silane replaces the silane used in this procedure.
- I ⁇ is prepared according to the same operating procedures (R3, R4, R5, R7) used for the synthesis of IR except that N-trifluoroacetyl- (3-cyano) - (4-methoxy) -aniline replaces the aniline used in the operating mode R3.
- I ⁇ is prepared according to the same operating procedures (R3, R4, R5, R7) used for the synthesis of IR except that N-trifluoroacetyl- (3-methyl) - (5-cyanc) -aniline replaces the aniline used in the operating mode R3.
- Iz is prepared according to the same operating procedures used for the synthesis of IR except that chloromethyl- (4-methoxy-phenyl) -dimethyl-silane replaces the silane used in procedure R3.
- Flash purification of the oil obtained on a silica column (90/10 Hexane / Ethyl ether) makes it possible to obtain, in the majority fraction, the expected product in the form of a light yellow oil (550 mg, 60%).
- Flash purification of the oil obtained on a silica column (90/10 Hexane / ethyl ether) makes it possible to obtain, in the majority fraction, the expected product in the form of a light yellow oil (178 mg, 20%).
- Trimethylborate (268 ⁇ l, 2.4 mmol, 3 eq.) is then added at this same temperature.
- the reaction mixture is stirred 30 minutes at -78 ° C then warmed to room temperature over 2 hours.
- N-methyl-morpholine oxide is then added to the solution under positive pressure of argon and then the medium is heated at reflux for 8 hours.
- the resulting solution is cooled and then diluted in 100ml of ethyl ether and hydrolyzed with 25ml of water.
- the organic phase is again washed with water until neutral pH and then dried over magnesium sulfate, filtered and evaporated.
- the resulting solution is diluted in 100 ml of ethyl ether and hydrolyzed with 10 ml of 5N HCl.
- the sentence organic is washed with a saturated sodium chloride solution to neutral pH then dried over magnesium sulfate, filtered and evaporated.
- Flash purification of the oil obtained on a silica column (80/20 petroleum ether / ethyl ether) allows the expected product to be obtained in the majority fraction in the form of a light yellow oil (35%).
- the resulting solution is diluted in 250ml of ethyl ether and hydrolyzed with 25ml of IN HCl.
- the organic phase is again washed with water until neutral pH and then dried over magnesium sulfate, filtered and evaporated.
- This compound is prepared from (IAA) (400 mg, O. mmol) and trimethylsilylisocyanate (160 ⁇ l, 1.2 mmol, 1.5 eq.) According to the procedure used for the preparation of
- This compound is prepared from (IAA) (300 mg, O. mm mmol) and chlorotrimethylsilane (84 ⁇ l, 0.66 mmol, 1.1 eq.) According to the procedure used for the preparation of IAQ-
- Flash purification of the oil obtained on a silica column (90/10 Hexane / Ethyl ether) makes it possible to obtain in the majority fraction the expected product in the form of a light yellow oil (192 mg, 65%) whose 1 H NMR spectrum is consistent with the structure of the expected product.
- This compound is prepared from (IAA) (400 mg, 0.8 mmol) and ethyl trifluoroacetate (114 ⁇ l, 0.96 mmol, 1.1 eq.) According to the procedure used for the preparation of IAQ.
- This compound is prepared from (IAA) (400mg, 0.8mmole) and acetyl chloride according to the procedure used for the preparation of IAQ-
- the NIH R spectrum is in agreement with the structure of the expected product.
- the resulting solution is heated for 1 hour 30 minutes to 140 ° C. then cooled and diluted in ethyl ether.
- the organic phase is washed with a saturated NaHCO3 solution and then a saturated sodium chloride solution until neutral pH and finally, dried over magnesium sulfate, filtered and evaporated.
- the 3-thienyl-boronic acid (230 mg, l. Mmol, 1.5 eq.) Is then added to the medium and then a 2N aqueous solution of a2CO3 (1.2 ml, 2.4 mmol, 2 eq.). The solution is stirred at reflux for 5 hours then cooled and diluted in ethyl ether. The organic phase is washed to neutral pH with a saturated solution of sodium chloride and then dried over magnesium sulfate, filtered and evaporated.
- Flash purification of the oil obtained on a silica column (90/10 petroleum ether / ethyl ether) allows the expected product to be obtained in the majority fraction in the form of an orange oil (404 mg, 67%) .
- the dark oil obtained after evaporation of the volunteers is diluted in DMSO (- 10 ml) and the resulting solution is treated with potassium fluoride dihydrate (5 eq.) For 2 hours at room temperature.
- reaction medium is then diluted in ethyl ether and then washed with water until neutral pH.
- the organic phase is dried over magnesium sulfate, filtered and evaporated.
- Flash purification of the oil obtained on a silica column (90/10 petroleum ether / ethyl ether) makes it possible to obtain, in the majority fraction, the expected product in the form of a light yellow oil (HOmg).
- reaction medium is heated at 100 ° C. for 24 hours then cooled and diluted in ethyl ether.
- the organic phase is washed with water until neutral pH, dried over magnesium sulfate, filtered and evaporated. Purification on a silica column makes it possible to obtain 9.5 g (45%) of a clear oil, the 1 H NMR spectrum conforms to the structure of the expected compound.
- the medium is extracted with ethyl ether, washed with a saturated sodium chloride solution until neutral, then the organic phase is dried over magnesium sulfate, filtered and evaporated. Purification on a silica column makes it possible to obtain a light yellow oil (227 mg; 60%).
- This compound is prepared from HBA (500 mg, 0.85) and phenyl-methyl-chlorosilane (273 mg, 1.7 mg, 1.2 eq.) According to the procedure used for the synthesis of IBA- Purification on a silica column makes it possible to obtain a clear oil (125mg, 35%).
- This compound is prepared from HBA (500 mg, 0.85 mmol) and cyclohexyl-dimethyl-chlorosilane (200 mg, 1.13 mmol, 1.3 eq.) According to the procedure used for the synthesis of IBA- Purification on a silica column makes it possible to obtain a clear oil (147 mg; 44%) whose 1 H NMR spectrum is in agreement with the structure of the expected product.
- This compound is prepared from HBA (500 mg, 0.85 mmol) and (2-thienyl) -dimethyl-chlorosilane (211 mg, 1.13 mmol, 1.3 eq.) According to the procedure used for the synthesis of IBA- Purification on a column of silica provides a clear oil (155mg, 47%).
- This compound is prepared from HBA (500 mg, 0.85 mmol) and (3-thienyl) -dimethyl-chlorosilane (200 mg, 1.13 mmol, 2.3 eq.) According to the procedure used for the synthesis of IBA- Purification on a column of silica provides a clear oil (150mg, 42%).
- This compound is prepared from HBA (500 mg, 0.85 mmol) and (2-cyano-phenyl) -dimethyl-chlorosilane (222 mg, 1.13 mmol, 1.3 eq) according to the procedure used for the synthesis of IBA- Purification on a column silica provides a clear oil (160mg, 75%).
- This compound is prepared from HBA (500 mg, 0.85 mmol) and (2,6-dimethyl-phenyl) -dimethyl-chlorosilane (225 mg, 1.13 mmol, 1.3 eq) according to the procedure used for the synthesis of IBA- Purification on a silica column, a clear oil (105 mg, 28%) is obtained, the 1 H NMR spectrum is in agreement with the structure of the expected product.
- This compound is prepared from HBA (500 mg, 0.85 mmol) and (3-pyridyl) -dimethyl-chlorosilane (205 mg, 1.13 mmol, 1.3 eq) according to the procedure used for the synthesis of IBA- Purification on a silica column provides a clear oil (135mg, 48%).
- This compound is prepared from IIBA (500mg, 0.85mmole) and (3-cyano-propyl) -dimethyl-chlorosilane (187 ⁇ l, 1.13, 1.3eq.) According to the procedure used for the synthesis of IBA- Purification on a column silica provides a clear oil (176mg, 62%).
- the medium is then extracted with ethyl ether and the organic phase is washed with water, dried over magnesium sulfate, filtered and evaporated. Purification on a silica column gives an oil which is dissolved in ethylamine (85ml, 1.9M in ethanol) and stirred with 3A molecular sieve for 60 hours. The medium is then filtered through Celite and the volatiles evaporated under vacuum.
- the resulting oil is then rediluted in absolute ethanol and the solution cooled to O'C.
- Sodium borohydride is added in portions to the reaction medium and the stirring is further continued for 2 hours at room temperature.
- the ethanol is then evaporated and the oil obtained is diluted in ethyl acetate and washed with 2x50ml of water.
- the organic phase is dried over magnesium sulfate, filtered and evaporated.
- Dichloromethane / Methanol / Ammonia 90/9/1) allows the expected product to be obtained in the majority fraction in the form of a light yellow oil (4.2g, 85%).
- This compound is prepared from HBJ and 1-bromo-3-methyl-3-methoxy-butyne according to the procedure used for the preparation of (I ⁇ j) •
- This compound is obtained from (E) -N-ethyl-N- (6,6-dimethyl-2-hepten-4-ynyl) - 3-hydroxy benzy ⁇ lamine (HA) (500mg, 1.84mmol) and of (chloromethyl) - [ ⁇ N, N '-acetyl -phenyl -amino ⁇ -methyl] -dimethyl- -silane (prepared by the action of bis (chloro-methyl) -dimethyl-silane with acetaniline) according to the procedure used for the preparation of (IA) then reduction of the intermediate thus formed by lithium aluminum hydride Purification on a silica column makes it possible to obtain in the majority fraction the expected product in the form of an oil clear (35%).
- TRIS-HC1 0.1M pH 7.5 955 ⁇ l
- the reaction was preincubated 15 min at 37 ° C before initiating the reaction by the addition of 2 mM NADPH: 10 .mu.l. Incubation of the reaction system 60 'at 37 ° C with shaking. Saponification by saponification mixture (1 ml) 60 'at room temperature. Extraction with petroleum ether 3 times 4 ml. We go to the vortex. Centrifuge 10 'at 3000 rpm. We recover the upper phase. Evaporation under N2. Resumption of the residue in 100 ⁇ l of ethyl acetate. Deposit of 50 ⁇ l on a CCM glass plate: Merck ref. Silica gel 60F 254 with concentration zone, migration solvent: hexane / ethyl acetate: 97/3. Reading the Berthold scanner.
- the Squalene solution (1 4 C) is introduced in a volume of 10 ⁇ l (1 ⁇ l of mother solution + 9 ⁇ l of Tween 80 in 0.075% acetone).
- FAD 0, lmM SIGMA ref.
- DHF dihydroxyfumaric acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7504983A JPH09500635A (ja) | 1993-07-22 | 1994-07-22 | 新規なシリルベンジルアミン誘導体、その塩類、製法、およびそれを含む薬剤組成物 |
EP94922295A EP0710241A1 (fr) | 1993-07-22 | 1994-07-22 | Nouveaux derives de benzylamines silylees, leurs sels, leurs procedes de fabrication et les compositions pharmaceutiques les renfermant |
AU73467/94A AU7346794A (en) | 1993-07-22 | 1994-07-22 | Novel silylated benzylamine derivatives, salts thereof, methods of manufacture and pharmaceutical compositions containing them |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9309025A FR2707989B1 (fr) | 1993-07-22 | 1993-07-22 | Nouveaux dérivés de benzylamines silylées, leurs sels, leurs procédés de fabrication et les compositions pharmaceutiques les renfermant. |
FR93/09025 | 1993-07-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995003313A1 true WO1995003313A1 (fr) | 1995-02-02 |
Family
ID=9449506
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1994/000921 WO1995003313A1 (fr) | 1993-07-22 | 1994-07-22 | Nouveaux derives de benzylamines silylees, leurs sels, leurs procedes de fabrication et les compositions pharmaceutiques les renfermant |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0710241A1 (fr) |
JP (1) | JPH09500635A (fr) |
AU (1) | AU7346794A (fr) |
CA (1) | CA2167821A1 (fr) |
FR (1) | FR2707989B1 (fr) |
WO (1) | WO1995003313A1 (fr) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000076523A1 (fr) * | 1999-06-11 | 2000-12-21 | Allergan Sales, Inc. | Procedes de modulation de l'activite du recepteur fxr |
WO2001055086A1 (fr) * | 2000-01-28 | 2001-08-02 | Novo Nordisk A/S | Derives d'acide propionique a substitution alkynyle et leur utilisation pour lutter contre le diabete et l'obesite |
AU759266B2 (en) * | 1997-05-13 | 2003-04-10 | Pola Chemical Industries Inc. | Amine derivatives |
US6569901B2 (en) | 2000-01-28 | 2003-05-27 | Novo Nordisk A/S | Alkynyl-substituted propionic acid derivatives, their preparation and use |
US6939853B2 (en) | 2001-12-29 | 2005-09-06 | Novo Nordisk A/S | Combined use of a GLP-1 compound and another drug for treating dyslipidemia |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4670421A (en) * | 1982-07-12 | 1987-06-02 | American Cyanamid Company | Antiatherosclerotic silanes |
EP0464852A1 (fr) * | 1990-07-05 | 1992-01-08 | Merrell Pharmaceuticals Inc. | Nouveau 2,6-dialkyl-4-silyl-phénols comme agents antiathérosclérotiques et comme antioxydants |
EP0464844A1 (fr) * | 1990-07-05 | 1992-01-08 | Merrell Dow Pharmaceuticals Inc. | Dérivés de bis (4-(2,6-dialkyl)phénol)silane comme agents antiathérosclérotiques et comme antioxydants |
-
1993
- 1993-07-22 FR FR9309025A patent/FR2707989B1/fr not_active Expired - Fee Related
-
1994
- 1994-07-22 JP JP7504983A patent/JPH09500635A/ja active Pending
- 1994-07-22 AU AU73467/94A patent/AU7346794A/en not_active Abandoned
- 1994-07-22 EP EP94922295A patent/EP0710241A1/fr not_active Withdrawn
- 1994-07-22 WO PCT/FR1994/000921 patent/WO1995003313A1/fr not_active Application Discontinuation
- 1994-07-22 CA CA002167821A patent/CA2167821A1/fr not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4670421A (en) * | 1982-07-12 | 1987-06-02 | American Cyanamid Company | Antiatherosclerotic silanes |
EP0464852A1 (fr) * | 1990-07-05 | 1992-01-08 | Merrell Pharmaceuticals Inc. | Nouveau 2,6-dialkyl-4-silyl-phénols comme agents antiathérosclérotiques et comme antioxydants |
EP0464844A1 (fr) * | 1990-07-05 | 1992-01-08 | Merrell Dow Pharmaceuticals Inc. | Dérivés de bis (4-(2,6-dialkyl)phénol)silane comme agents antiathérosclérotiques et comme antioxydants |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU759266B2 (en) * | 1997-05-13 | 2003-04-10 | Pola Chemical Industries Inc. | Amine derivatives |
WO2000076523A1 (fr) * | 1999-06-11 | 2000-12-21 | Allergan Sales, Inc. | Procedes de modulation de l'activite du recepteur fxr |
WO2001055086A1 (fr) * | 2000-01-28 | 2001-08-02 | Novo Nordisk A/S | Derives d'acide propionique a substitution alkynyle et leur utilisation pour lutter contre le diabete et l'obesite |
US6569901B2 (en) | 2000-01-28 | 2003-05-27 | Novo Nordisk A/S | Alkynyl-substituted propionic acid derivatives, their preparation and use |
US7202213B2 (en) | 2000-01-28 | 2007-04-10 | Novo Nordisk A/S | Combination therapy using a dual PPAR-α/PPAR-γ activator and a GLP-1 derivative for the treatment of metabolic syndrome and related diseases and disorders |
US6939853B2 (en) | 2001-12-29 | 2005-09-06 | Novo Nordisk A/S | Combined use of a GLP-1 compound and another drug for treating dyslipidemia |
Also Published As
Publication number | Publication date |
---|---|
JPH09500635A (ja) | 1997-01-21 |
CA2167821A1 (fr) | 1995-02-02 |
EP0710241A1 (fr) | 1996-05-08 |
FR2707989A1 (fr) | 1995-01-27 |
AU7346794A (en) | 1995-02-20 |
FR2707989B1 (fr) | 1995-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1720872A1 (fr) | Derives d'aryl- et d'heteroaryl-piperidinecarboxylates, leur preparation et leur application comme inhibiteurs de l'enzyme faah | |
AU652088B2 (en) | Chemical compounds | |
EP1720848A1 (fr) | Derives de alkylpiperazine- et alkylhomopiperazine- carboxylates, leur preparation et leur application en tant qu'inhibiteurs de l'enzyme faah | |
EP1590321B1 (fr) | Derives d' arylalkylcarbamates, leur preparation et leur application en therapeutique | |
LU85551A1 (fr) | Nouveaux composes azoliques,leur preparation et leur utilisation comme antifongiques et fongicides | |
EP1497255A2 (fr) | Procedes de preparation de combretastatines | |
FR2496103A1 (fr) | Nouveaux derives du benzopyranne et du benzothiopyranne, leur preparation et leur application comme medicaments | |
WO1995003313A1 (fr) | Nouveaux derives de benzylamines silylees, leurs sels, leurs procedes de fabrication et les compositions pharmaceutiques les renfermant | |
CA1073919A (fr) | Derives de l'acetylene contenant du silicium et de l'azote | |
EP2234966B1 (fr) | Derives d'azetidines, leur preparation et leur application en therapeutique | |
EP0374041A1 (fr) | Médicaments à base de dérivés de la benzothiazolamine-2, dérivés et leur préparation | |
EP0625153B1 (fr) | Derive de l'isoindolinone, sa preparation et les compositions pharmaceutiques qui le contiennent | |
CA2074365A1 (fr) | Derives de l'uree, leur preparation et les medicaments les contenant | |
EP1720829A1 (fr) | Derives d' heteroaryl-alkylcarbamates, leur preparation et leur application comme inhibiteurs de l'enzyme faah | |
FR2772766A1 (fr) | Nouveaux composes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
FR2520741A1 (fr) | Nouveaux derives du benzothiophene, leur preparation et leur utilisation comme medicaments | |
FR2719047A1 (fr) | Nouveaux dérivés de benzylamines, leur procédé de fabrication et les compositions pharmaceutiques les renfermant. | |
CA2196102A1 (fr) | Derives de streptogramine, leur preparation et les compositions pharmaceutiques qui les contiennent | |
EP0151052B1 (fr) | Aminoéthylimidazole, composition pharmaceutique en contenant et procédé de préparation | |
EP0869952A1 (fr) | Derives de 5-naphtalen-1-y1-1,3-dioxanes, leur preparation et leur application en therapeutique | |
FR2745572A1 (fr) | Nouveaux sulfonamides derives de benzylamines, leurs sels, ainsi que leurs procedes de fabrication, les compositions pharmaceutiques et leur utilisation comme medicaments | |
EP1131293A1 (fr) | Derives de 1-aminoethylquinoleine pour le traitement de l'incontinence urinaire | |
CH682322A5 (fr) | ||
WO1996001830A1 (fr) | Derives de silylmethyl-anilines, leurs procedes de fabrication et leur utilisation comme medicament | |
FR2791676A1 (fr) | Nouveaux derives de [(2-substitue-5-[thienyl])-benzyl]- [2-([isopropoxy-5-fluoro]-phenoxy) ethyl]-amine, leur procede de preparation et leur utilisation a titre de medicaments |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP NZ US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 1996 578668 Country of ref document: US Date of ref document: 19960119 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2167821 Country of ref document: CA Ref document number: 1994922295 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 269816 Country of ref document: NZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1994922295 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1994922295 Country of ref document: EP |